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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the 
current coronavirus disease 2019 (COVID-19) pandemic. Many patients with severe COVID-19 
develop sepsis. Cardiometabolic traits have been associated with increased risk of severe 
COVID-19 and sepsis, however it is difficult to infer causal effects from observational studies 
due to the possibility that any identified associations may be attributable to confounding. Here, 
we leverage data from large-scale genetic association studies to identify genetic proxies for body 
mass index (BMI), lifetime smoking score, low-density lipoprotein cholesterol (LDL-C), systolic 
blood pressure (SBP) and type 2 diabetes mellitus (T2DM) liability, and apply these in 
Mendelian randomization (MR) analyses investigating their associations with risk of sepsis and 
severe COVID-19. Through leverage of randomly allocated genetic variants, this approach can 
better overcome the confounding that hinders causal inference in observational study. 
The methods and data sources relating to this work are described in detail elsewhere.1 
Briefly, genetic variants selected as instrumental variables were uncorrelated (r2 < 0.001) single-
nucleotide polymorphisms associated with the corresponding exposure trait at genome-wide 
significance (p < 5x10-8) in previously published genome-wide association study (GWAS) 
analyses.1 Summary genetic association estimates for sepsis were obtained from the UK Biobank 
(10,154 cases and 452,764 controls) and HUNT Study (2301 cases and 67,121 controls).1 We 
defined sepsis using a previously published list of explicit ICD-9 and ICD-10 codes derived by a 
panel of experts in critical care, infectious diseases, pediatrics, and sepsis epidemiology.1 This 
was a binary variable based on the presence of one or more codes as a main or secondary 
diagnosis in the hospital inpatient admissions data or as a primary or secondary cause of death in 
the death registry data.1 Sepsis cases were not restricted to those with presumed bacterial 









failure were obtained from a GWAS performed in 1610 cases and 2205 controls (with no or mild 
COVID-19 symptoms) in Italy and Spain.2 Genetic association estimates for hospitalization with 
COVID-19 were obtained from release 3 (June 2020) of the COVID-19 Host Genetics Initiative 
GWAS, which considered 3199 cases and 897,488 controls from the general population.3 The 
main MR analyses were performed using the inverse-variance weighted method and sensitivity 
analyses were performed using the weighted median and the MR-Egger methods.4  All summary 
data used in this work are publicly available, and obtained relevant participant consent and 
ethical approval.  
The MR analyses showed that higher genetically proxied BMI and lifetime smoking 
score were associated with increased risk of developing sepsis in both UK Biobank and the 
HUNT Study. Both higher genetically proxied BMI and lifetime smoking score were also 
associated with increased risk of severe COVID-19 with respiratory failure and hospitalization 
with COVID-19 (Figure). Similar estimates were obtained in MR sensitivity analyses, although 
with wider 95% confidence intervals (Figure). There was no strong evidence supporting an 
association of genetically proxied LDL-C, SBP or T2DM liability with risk of sepsis or severe 
COVID-19. 
Taken together, our findings support the hypothesis that elevated BMI and smoking 
increase susceptibility to sepsis and severe COVID-19. A number of potential mechanisms may 
be underlying this causal relationship, most notably immune dysregulation.5 Furthermore, 
obesity and smoking status are both modifiable traits that may be targeted to reduce COVID-19 
associated morbidity and mortality. 
Our study has a number of strengths. We considered distinct data sources and performed 









variants. While the results were consistent, particular methods produced wider confidence 
intervals than others, in-keeping with known differences in their statistical power.4 Furthermore, 
we considered COVID-19 cases that were severe enough to require hospitalization, and as such 
there was less risk of selection bias related to COVID-19 diagnosis, as all such patients would be 
expected to undergo testing.  
Our study also has limitations. Our investigation was based on European ancestry 
participants. Initiatives to identify genetic factors related to risk of severe COVID-19 are 
ongoing,3 and such work will also expand to other ethnic groups. It is important to appreciate 
that MR effect estimates should not be directly extrapolated to predict the effect of an 
intervention, but should rather be used as evidence to support a causal relationship. Although we 
explored the association of genetically proxied T2DM liability with risk of sepsis and severe 
COVID-19, we were not able to assess the effect of a clinical T2DM diagnosis directly, as for 
most individuals, presence of these genetic variants does not necessarily result in a T2DM 
diagnosis. Thus, there may be a causal relationship between diabetes (or glycemic control) and 
severe COVID-19 that our study could not detect. Finally, our analyses also had limited 
statistical power, as apparent from the confidence intervals of the results. Given that the genetic 
variants used to proxy SBP, LDL-C and T2DM explained 2.9%, 7.9% and 16.3% of the variance 
in these traits respectively,1 our main MR analysis had 80% power to detect an odds ratio for 
hospitalization with COVID-19 of 1.29 for SBP, 1.18 for LDL-C and 1.12 for T2DM liability.  
In conclusion, we leveraged large-scale genetic summary data to investigate the effects of 
cardiometabolic traits on risk of sepsis and severe COVID-19. Our findings support causal 
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Figure. Results of Mendelian randomization analyses investigating the association of genetically 
proxied cardiometabolic traits with risk of sepsis in UK Biobank (top left; 10,154 cases and 
452,764 controls) and the HUNT Study (top right; 2301 cases and 67,121 controls), and risk of 
severe COVID-19 with respiratory failure (bottom left; 1610 cases and 2205 controls) and 
hospitalization (bottom right; 3199 cases and 897,488 controls).  
Results are expressed per standard deviation increase in genetically proxied levels of the 
exposure for continuous traits (BMI, LDL, SBP, and smoking), and per unit increase in log odds 
ratio for genetically proxied T2DM liability. The MR-Egger intercept p-value was >0.05 for all 
analyses. BMI: body mass index; IVW: inverse-variance weighted Mendelian randomization; 
LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; Smoking: lifetime 
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